| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5689226 | European Urology | 2017 | 10 Pages |
Abstract
It is challenging to determine whether tumors confined to the prostate are aggressive, leading to significant undertreatment and overtreatment. We validated a test based on prostate tumor DNA that improves estimations of relapse risk, and that can help guide treatment planning.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Emilie Lalonde, Rached Alkallas, Melvin Lee Kiang Chua, Michael Fraser, Syed Haider, Alice Meng, Junyan Zheng, Cindy Q. Yao, Valerie Picard, Michele Orain, Helène Hovington, Jure Murgic, Alejandro Berlin, Louis Lacombe, Alain Bergeron, Yves Fradet,